KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by State Street Corp

State Street Corp lifted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 68.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,271,609 shares of the specialty pharmaceutical company's stock after purchasing an additional 515,179 shares during the period. State Street Corp owned about 2.94% of KalVista Pharmaceuticals worth $14,725,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KALV. nVerses Capital LLC bought a new stake in KalVista Pharmaceuticals during the 2nd quarter valued at $25,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock valued at $96,000 after buying an additional 3,328 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $126,000. SG Americas Securities LLC acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $153,000. Finally, Quest Partners LLC purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $175,000.

KalVista Pharmaceuticals Price Performance

KALV stock traded down $0.07 during trading on Wednesday, hitting $8.76. 125,256 shares of the company traded hands, compared to its average volume of 478,971. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.97 and a 1 year high of $16.88. The company has a market cap of $432.90 million, a PE ratio of -2.41 and a beta of 0.85. The stock's 50-day simple moving average is $10.18 and its 200 day simple moving average is $11.57.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 7,627 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total value of $74,363.25. Following the completion of the sale, the chief executive officer now directly owns 274,596 shares in the company, valued at $2,677,311. This represents a 2.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 8,077 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock valued at $304,086 in the last three months. 10.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have weighed in on KALV. Cantor Fitzgerald reissued an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, Bank of America began coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a "buy" rating and a $22.00 price objective for the company.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).